Identification
NameOmbitasvir
Accession NumberDB09296
TypeSmall Molecule
GroupsApproved
Description

Ombitasvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [8]. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Ombitasvir. Ombitasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly [FDA Label]. The barrier for develoment of resistance to NS5A inhibitors is lower than that of NS5B inhibitors, another class of DAAs [5].

In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Ombitasvir as a first line therapy option when used in combination with other antivirals for genotypes 1a, 1b, and 4 [8]. Depending on the genotype, Ombitasvir is often used in combination with other antivirals such as Dasabuvir, Paritaprevir, Ritonavir, and Ribavirin with the intent to cure, or achieve a sustained virologic response (SVR), after 12 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality [6]. Treatment with direct acting antivirals such as Ombitasvir is associated with very minimal side effects, with the most common being headache and fatigue [FDA Label]. Lack of significant side effects and short duration of therapy is a considerable advantage over older interferon-based regimens, which were limited by infusion site reactions, reduced blood count, and neuropsychiatric effects [7].

Ombutasvir first came on the market as a fixed-dose combination product with Dasabuvir, Paritaprevir, and Ritonavir as the FDA-approved product Viekira Pak. First approved in December 2014, Viekira Pak is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis.

Ombutasvir is also available as a fixed-dose combination product with Paritaprevir and Ritonavir as the FDA- and Health Canada-approved product Technivie. First approved in July 2015, Technivie is indicated in combination with Ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis.

In Canada, Ombutasvir is also available as a fixed-dose combination product with Dasabuvir, Paritaprevir, and Ritonavir as the Health Canada-approved, commercially available product Holkira Pak. First approved in January 2015, Holkira Pak is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a with or without cirrhosis.

Structure
Thumb
Synonyms
dimethyl ([(2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl]bis{(4,1-phenylene)carbamoyl(2S)pyrrolidine-2,1-diyl[(2S)-3-methyl-1-oxobutane-1,2-diyl]})biscarbamate
External IDs ABT 267 / ABT-267 / ABT267
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Holkira PakKit; TabletOralAbbvie2015-01-06Not applicableCanada
TechnivieTabletOralAbbvie2015-11-24Not applicableCanada
Viekira PakKitAbbvie2014-12-19Not applicableUs
Viekira XRKitAbbvie2016-07-22Not applicableUs
Categories
UNII2302768XJ8
CAS number1258226-87-7
WeightAverage: 894.127
Monoisotopic: 893.505112145
Chemical FormulaC50H67N7O8
InChI KeyPIDFDZJZLOTZTM-KHVQSSSXSA-N
InChI
InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1
IUPAC Name
methyl N-[(2S)-1-[(2S)-2-({4-[(2S,5S)-1-(4-tert-butylphenyl)-5-{4-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]pyrrolidine-2-amido]phenyl}pyrrolidin-2-yl]phenyl}carbamoyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
SMILES
COC(=O)N[[email protected]@H](C(C)C)C(=O)N1CCC[[email protected]]1C(=O)NC1=CC=C(C=C1)[[email protected]@H]1CC[[email protected]](N1C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(NC(=O)[[email protected]@H]2CCCN2C(=O)[[email protected]@H](NC(=O)OC)C(C)C)C=C1
Pharmacology
Indication

When used in combination with Paritaprevir and Ritonavir (as the fixed dose product Technivie), Ombitasvir is indicated in combination with Ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis [9].

When used in combination with Paritaprevir, Ritonavir, and Dasabuvir (as the fixed dose product Viekira Pak), Ombitasvir is indicated for the treatment of HCV genotype 1b and ,when combined with Ribavirin, for the treatment of HCV genotype 1a [FDA Label]

Structured Indications
Pharmacodynamics

Ombitasvir is classified as a direct acting antiviral and acts against HCV to inhibit viral replication [FDA Label].

Mechanism of action

Ombitasvir is an inhibitor of the HCV non-structural protein 5A. While the precise role of this protein is unknown, it is essential to viral replication and virion assembly [FDA Label]. Potential modes of action of NS5A inhibitors like Elbasvir include blocking signaling interactions, redistribution of NS5A from the endoplasmic reticulum to the surface of lipid droplets, and modification of the HCV replication complex [5].

TargetKindPharmacological actionActionsOrganismUniProt ID
Nonstructural protein 5AProteinyes
inhibitor
Hepatitis C virusQ5L478 details
Related Articles
Absorption

Ombitasvir reaches peak plasma concentration 5 hours after administration [FDA Label]. It has an absolute bioavailability of 48%. Taking ombitasvir with high or normal fat meals increases exposure by 1.76 or 1.82 fold respectively.

Volume of distribution

Ombitasvir has a volume of distribution at steady state of 173 liters [FDA Label].

Protein binding

Ombitasvir is 99.9% bound to human plasma proteins [FDA Label].

Metabolism

Ombitasvir is mainly metabolized by amide hydrolysis followed by CYP2C8-mediated oxidative metabolism [FDA Label].

Route of elimination

Ombitasvir is mainly excreted in the feces (90.2%) with very little excreted in the urine (1.91%) [FDA Label]. 87.8% and 0.03% of the dose excreted in the feces and urine respectively is present as the parent compound.

Half life

Ombitasvir has a half life of elimination of 21-25 hours [FDA Label]

Clearance

Clearance of Ombitasvir has not been determined.

Toxicity

The most common adverse effects of Viekira Pak either in combination with or without Ribavirin were pruritus, nausea, insomnia, and asthenia [FDA Label]. The most common adverse effects of Technivie with or without Ribavirin were asthenia, fatigue, nausea, insomnia and pruritus [9].

Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Ombitasvir can be increased when it is combined with Abiraterone.Approved
AcetaminophenThe serum concentration of Ombitasvir can be increased when it is combined with Acetaminophen.Approved
AfatinibThe serum concentration of Ombitasvir can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Ombitasvir can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Ombitasvir can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Ombitasvir can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Ombitasvir.Approved, Illicit
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Ombitasvir.Approved, Illicit, Investigational
AmantadineThe serum concentration of Ombitasvir can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Ombitasvir can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Amiodarone can be increased when it is combined with Ombitasvir.Approved, Investigational
AmitriptylineThe serum concentration of Ombitasvir can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Ombitasvir can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Ombitasvir can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Ombitasvir can be increased when it is combined with Amsacrine.Approved
AstemizoleThe serum concentration of Ombitasvir can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Ombitasvir can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Ombitasvir can be increased when it is combined with Atenolol.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Ombitasvir.Approved
AzelastineThe serum concentration of Ombitasvir can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Ombitasvir can be increased when it is combined with Azithromycin.Approved
BenzocaineThe serum concentration of Ombitasvir can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Ombitasvir can be increased when it is combined with Bepridil.Approved, Withdrawn
BiperidenThe serum concentration of Ombitasvir can be increased when it is combined with Biperiden.Approved
BosutinibThe serum concentration of Ombitasvir can be increased when it is combined with Bosutinib.Approved
BromocriptineThe serum concentration of Ombitasvir can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be increased when it is combined with Ombitasvir.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Ombitasvir can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Ombitasvir can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Ombitasvir can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Ombitasvir can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Ombitasvir can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Ombitasvir can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Ombitasvir can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarvedilolThe serum concentration of Ombitasvir can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Ombitasvir can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Ombitasvir can be decreased when combined with Celecoxib.Approved, Investigational
ChloroquineThe serum concentration of Ombitasvir can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Ombitasvir can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Ombitasvir can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Ombitasvir can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Ombitasvir can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Ombitasvir can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Ombitasvir can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Ombitasvir can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Ombitasvir can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Ombitasvir can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Ombitasvir can be increased when it is combined with Clarithromycin.Approved
ClofazimineThe serum concentration of Ombitasvir can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Ombitasvir can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClopidogrelThe serum concentration of Ombitasvir can be increased when it is combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Ombitasvir can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Ombitasvir can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Ombitasvir can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Ombitasvir can be increased when it is combined with Colforsin.Experimental
CrizotinibThe serum concentration of Ombitasvir can be increased when it is combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Ombitasvir can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Ombitasvir.Approved, Investigational, Vet Approved
CyclosporineThe serum concentration of Ombitasvir can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Ombitasvir can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Ombitasvir can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Ombitasvir can be increased when it is combined with Dactinomycin.Approved
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Ombitasvir.Approved
DasatinibThe serum concentration of Ombitasvir can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Ombitasvir can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Ombitasvir can be increased when it is combined with Deferasirox.Approved, Investigational
DesipramineThe serum concentration of Ombitasvir can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Ombitasvir can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Ombitasvir can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Ombitasvir can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Ombitasvir can be increased when it is combined with Diclofenac.Approved, Vet Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ombitasvir.Approved
DihydroergotamineThe serum concentration of Ombitasvir can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Ombitasvir can be increased when it is combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Ombitasvir can be increased when it is combined with Dipyridamole.Approved
DoxazosinThe serum concentration of Ombitasvir can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Ombitasvir can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Ombitasvir can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Ombitasvir can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Ombitasvir can be increased when it is combined with Dronedarone.Approved
EfavirenzThe metabolism of Ombitasvir can be decreased when combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Ombitasvir can be increased when it is combined with Elbasvir.Approved
EnalaprilThe serum concentration of Ombitasvir can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Ombitasvir can be increased when it is combined with Enzalutamide.Approved
ErgonovineThe serum concentration of Ombitasvir can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Ombitasvir can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Ombitasvir can be decreased when it is combined with Erythromycin.Approved, Vet Approved
EstramustineThe serum concentration of Ombitasvir can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Ombitasvir can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Ombitasvir can be decreased when it is combined with Estrone.Approved
EtoposideThe serum concentration of Ombitasvir can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Ombitasvir can be increased when it is combined with Etravirine.Approved
FelodipineThe serum concentration of Ombitasvir can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Ombitasvir.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Ombitasvir can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Ombitasvir can be increased when it is combined with Fidaxomicin.Approved
FluconazoleThe serum concentration of Ombitasvir can be increased when it is combined with Fluconazole.Approved
FluoxetineThe serum concentration of Ombitasvir can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Ombitasvir can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Ombitasvir can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Ombitasvir can be increased when it is combined with Flurazepam.Approved, Illicit
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Ombitasvir.Approved
FluvoxamineThe serum concentration of Ombitasvir can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe serum concentration of Ombitasvir can be decreased when it is combined with Fosphenytoin.Approved
GefitinibThe serum concentration of Ombitasvir can be increased when it is combined with Gefitinib.Approved, Investigational
GemfibrozilThe serum concentration of Ombitasvir can be increased when it is combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Ombitasvir can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Ombitasvir can be increased when it is combined with Glyburide.Approved
Gramicidin DThe serum concentration of Ombitasvir can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Ombitasvir can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Ombitasvir can be increased when it is combined with Haloperidol.Approved
HydrocortisoneThe serum concentration of Ombitasvir can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IdelalisibThe serum concentration of Ombitasvir can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Ombitasvir can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Ombitasvir can be increased when it is combined with Imipramine.Approved
IndinavirThe serum concentration of Ombitasvir can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Ombitasvir can be increased when it is combined with Indomethacin.Approved, Investigational
IrbesartanThe metabolism of Ombitasvir can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe serum concentration of Ombitasvir can be increased when it is combined with Isavuconazonium.Approved, Investigational
ItraconazoleThe serum concentration of Ombitasvir can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ombitasvir can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ombitasvir can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Ombitasvir can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Ombitasvir can be increased when it is combined with Ketoconazole.Approved, Investigational
LansoprazoleThe serum concentration of Ombitasvir can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Ombitasvir can be increased when it is combined with Lapatinib.Approved, Investigational
LevofloxacinThe serum concentration of Ombitasvir can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Ombitasvir can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Ombitasvir can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Ombitasvir can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Ombitasvir can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Ombitasvir can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Ombitasvir can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Ombitasvir can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Ombitasvir can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Ombitasvir can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Ombitasvir can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Ombitasvir can be increased when it is combined with Lovastatin.Approved, Investigational
LumacaftorThe serum concentration of Ombitasvir can be increased when it is combined with Lumacaftor.Approved
MaprotilineThe serum concentration of Ombitasvir can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Ombitasvir can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Ombitasvir can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Ombitasvir can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Ombitasvir can be increased when it is combined with Meprobamate.Approved, Illicit
MethadoneThe serum concentration of Ombitasvir can be increased when it is combined with Methadone.Approved
MetoprololThe serum concentration of Ombitasvir can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Ombitasvir can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Ombitasvir can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Ombitasvir can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Ombitasvir can be increased when it is combined with Mifepristone.Approved, Investigational
MitomycinThe serum concentration of Ombitasvir can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Ombitasvir can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MorphineThe serum concentration of Ombitasvir can be increased when it is combined with Morphine.Approved, Investigational
NaltrexoneThe serum concentration of Ombitasvir can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Ombitasvir can be increased when it is combined with Naringenin.Experimental
NefazodoneThe serum concentration of Ombitasvir can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Ombitasvir can be decreased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Ombitasvir can be increased when it is combined with Neostigmine.Approved, Vet Approved
NicardipineThe serum concentration of Ombitasvir can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Ombitasvir can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Ombitasvir can be increased when it is combined with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Ombitasvir can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Ombitasvir can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Ombitasvir can be increased when it is combined with Nitrendipine.Approved
NorethisteroneThe serum concentration of Ombitasvir can be decreased when it is combined with Norethisterone.Approved
OmeprazoleThe serum concentration of Ombitasvir can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Ombitasvir can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Ombitasvir can be increased when it is combined with Paclitaxel.Approved, Vet Approved
Palmitic AcidThe serum concentration of Ombitasvir can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Ombitasvir can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Ombitasvir can be increased when it is combined with Paroxetine.Approved, Investigational
PerindoprilThe serum concentration of Ombitasvir can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe serum concentration of Ombitasvir can be decreased when it is combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Ombitasvir can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Ombitasvir can be increased when it is combined with Pimozide.Approved
PioglitazoneThe metabolism of Ombitasvir can be decreased when combined with Pioglitazone.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ombitasvir.Approved
Platelet Activating FactorThe serum concentration of Ombitasvir can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Ombitasvir can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Ombitasvir can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Ombitasvir can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Ombitasvir can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Ombitasvir can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe serum concentration of Ombitasvir can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Ombitasvir can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Ombitasvir can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Ombitasvir can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Ombitasvir can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Ombitasvir can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Ombitasvir can be increased when it is combined with Protriptyline.Approved
QuercetinThe serum concentration of Ombitasvir can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Ombitasvir can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Ombitasvir.Approved
QuinineThe serum concentration of Ombitasvir can be increased when it is combined with Quinine.Approved
RabeprazoleThe metabolism of Ombitasvir can be decreased when combined with Rabeprazole.Approved, Investigational
RanitidineThe serum concentration of Ombitasvir can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ombitasvir can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Ombitasvir can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Ombitasvir can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Ombitasvir can be decreased when it is combined with Reserpine.Approved
RifampicinThe serum concentration of Ombitasvir can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Ombitasvir can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe serum concentration of Ombitasvir can be increased when it is combined with Rilpivirine.Approved
RitonavirThe serum concentration of Ombitasvir can be increased when it is combined with Ritonavir.Approved, Investigational
RolapitantThe serum concentration of Ombitasvir can be increased when it is combined with Rolapitant.Approved
RosiglitazoneThe metabolism of Ombitasvir can be decreased when combined with Rosiglitazone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Ombitasvir.Approved
SaquinavirThe serum concentration of Ombitasvir can be decreased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Ombitasvir can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe serum concentration of Ombitasvir can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Ombitasvir can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Ombitasvir can be increased when it is combined with Sertraline.Approved
SimeprevirThe serum concentration of Ombitasvir can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Ombitasvir can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Ombitasvir.Approved, Investigational
SorafenibThe serum concentration of Ombitasvir can be increased when it is combined with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of Ombitasvir can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Ombitasvir can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Ombitasvir can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Ombitasvir can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Ombitasvir can be decreased when it is combined with Streptozocin.Approved
SulfamethoxazoleThe metabolism of Ombitasvir can be decreased when combined with Sulfamethoxazole.Approved
SulfinpyrazoneThe serum concentration of Ombitasvir can be increased when it is combined with Sulfinpyrazone.Approved
SumatriptanThe serum concentration of Ombitasvir can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Ombitasvir can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Ombitasvir can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Ombitasvir.Approved, Investigational
TacrolimusThe serum concentration of Ombitasvir can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Ombitasvir can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Ombitasvir can be increased when it is combined with Taurocholic Acid.Experimental
TelmisartanThe serum concentration of Ombitasvir can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Ombitasvir can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Ombitasvir can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Ombitasvir can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe metabolism of Ombitasvir can be decreased when combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Ombitasvir can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Ombitasvir can be increased when it is combined with Testosterone.Approved, Investigational
TicagrelorThe serum concentration of Ombitasvir can be increased when it is combined with Ticagrelor.Approved
TolvaptanThe serum concentration of Ombitasvir can be increased when it is combined with Tolvaptan.Approved
TrazodoneThe serum concentration of Ombitasvir can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Ombitasvir can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Ombitasvir can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Ombitasvir can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Ombitasvir can be increased when it is combined with Trimipramine.Approved
VenlafaxineThe serum concentration of Ombitasvir can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Ombitasvir can be decreased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Ombitasvir can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Ombitasvir can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Ombitasvir can be increased when it is combined with Vinorelbine.Approved, Investigational
ZimelidineThe serum concentration of Ombitasvir can be increased when it is combined with Zimelidine.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Shen J, Serby M, Surber B, Lee AJ, Ma J, Badri P, Menon R, Kavetskaia O, de Morais SM, Sydor J, Fischer V: Metabolism and Disposition of Pan-Genotypic Inhibitor of Hepatitis C Virus NS5A Ombitasvir in Humans. Drug Metab Dispos. 2016 Aug;44(8):1148-57. doi: 10.1124/dmd.115.067496. Epub 2016 May 13. [PubMed:27179128 ]
  2. DeGoey DA, Randolph JT, Liu D, Pratt J, Hutchins C, Donner P, Krueger AC, Matulenko M, Patel S, Motter CE, Nelson L, Keddy R, Tufano M, Caspi DD, Krishnan P, Mistry N, Koev G, Reisch TJ, Mondal R, Pilot-Matias T, Gao Y, Beno DW, Maring CJ, Molla A, Dumas E, Campbell A, Williams L, Collins C, Wagner R, Kati WM: Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014 Mar 13;57(5):2047-57. doi: 10.1021/jm401398x. Epub 2014 Jan 15. [PubMed:24400777 ]
  3. Keating GM: Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection. Drugs. 2016 Aug;76(12):1203-11. doi: 10.1007/s40265-016-0612-1. [PubMed:27401997 ]
  4. Macdonald A, Harris M: Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol. 2004 Sep;85(Pt 9):2485-502. [PubMed:15302943 ]
  5. Bagaglio S, Uberti-Foppa C, Morsica G: Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Drugs. 2017 May 12. doi: 10.1007/s40265-017-0753-x. [PubMed:28497432 ]
  6. Myers RP, Shah H, Burak KW, Cooper C, Feld JJ: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):19-34. Epub 2015 Jan 13. [PubMed:25585348 ]
  7. Dusheiko G: Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997 Sep;26(3 Suppl 1):112S-121S. [PubMed:9305675 ]
  8. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017. [Link]
  9. Dailymed: Technivie [Link]
External Links
ATC CodesJ05AX67 — Ombitasvir, paritaprevir and ritonavirJ05AX66 — Dasabuvir, ombitasvir, paritaprevir and ritonavir
AHFS Codes
  • 8:18.40.24
PDB EntriesNot Available
FDA labelDownload (540 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAbsolute Bioavailability1
1CompletedTreatmentHCV Infections1
1CompletedTreatmentHealthy Volunteers1
2Active Not RecruitingTreatmentChronic Hepatitis C Virus (HCV) Infection / Hepatitis C (HCV) / Hepatitis C Genotype 11
2CompletedTreatmentChronic Hepatitis C Infection3
2CompletedTreatmentChronic Hepatitis C Infection / Chronic Hepatitis C Virus (HCV) Infection1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Hepatitis C (HCV) / Hepatitis C Genotype 11
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Hepatitis C (HCV) / Hepatitis C Genotype 1a1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Hepatitis C Virus (HCV) Infection1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Compensated liver disease / Hepatitis C Virus (HCV)1
2CompletedTreatmentChronic Hepatitis C Virus Infection1
2CompletedTreatmentHepatitis C Virus (HCV)1
2CompletedTreatmentHepatitis C, Chronic1
2RecruitingTreatmentChronic Hepatitis C Virus (HCV) Infection1
2RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2, 3RecruitingTreatmentChronic Hepatitis C Infection / HBV Coinfection / Hepatitis B Reactivation1
3Active Not RecruitingTreatmentChronic Hepatitis C Virus (HCV) Infection Genotype 12
3Active Not RecruitingTreatmentHepatitis C, Acute1
3CompletedNot AvailableChronic Hepatitis C Infection1
3CompletedTreatmentChronic Hepatitis C Infection11
3CompletedTreatmentChronic Hepatitis C Infection / Chronic Hepatitis C Virus (HCV) Infection1
3CompletedTreatmentChronic Hepatitis C Infection / Chronic Kidney Disease (CKD) / Genotype 1a / Genotype 4 / HCV / IFN / PegIFN1
3CompletedTreatmentChronic Hepatitis C Infection / Compensated liver disease / Hepatitis C Virus (HCV)1
3CompletedTreatmentChronic Hepatitis C Virus2
3CompletedTreatmentChronic Hepatitis C Virus (HCV Infection Genotype 1)1
3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Cirrhosis, Decompensated / Hepatitis C Virus (HCV)1
3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Compensated Cirrhosis and Non-cirrhotics / Hepatitis C Virus Infection / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Compensated liver disease / End-Stage Renal Disease (ESRD) / Hepatitis C Virus (HCV) / Severe Renal Impairment1
3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Hepatitis C (HCV) / Hepatitis C Genotype 1a1
3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Hepatitis C Virus (HCV) / Liver Cirrhosis1
3CompletedTreatmentChronic Hepatitis C Virus / Hepatitis C Virus (HCV)1
3CompletedTreatmentHepatitis C Infection / Hepatitis C Virus (HCV)1
3CompletedTreatmentHepatitis C Virus (HCV)2
3RecruitingTreatmentChronic Hepatitis C Infection1
3WithdrawnTreatmentChronic Hepatitis C Virus1
4Active Not RecruitingTreatmentHepatitis C Virus (HCV)1
4Active Not RecruitingTreatmentHepatitis C, Chronic1
4RecruitingTreatmentChronic Hepatitis C Virus (HCV) Infection1
4RecruitingTreatmentHCV Coinfection1
Not AvailableActive Not RecruitingNot AvailableChronic Hepatitis C Virus (HCV) Infection / Liver Cirrhosis1
Not AvailableRecruitingNot AvailableHepatitis C, Chronic / Human Immunodeficiency Virus (HIV)1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Kit; tabletOral
Kit
TabletOral
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6703403 Yes1996-12-262016-12-26Us
US6037157 Yes1996-12-262016-12-26Us
US7364752 Yes2001-05-102021-05-10Us
US7148359 Yes2000-01-192020-01-19Us
US8268349 Yes2005-02-252025-02-25Us
US8399015 Yes2005-02-252025-02-25Us
US9139536 No2008-11-092028-11-09Us
US8685984 No2012-09-042032-09-04Us
US8466159 No2012-09-042032-09-04Us
US8642538 No2009-09-102029-09-10Us
US8501238 No2008-09-172028-09-17Us
US8680106 No2012-09-042032-09-04Us
US8492386 No2012-09-042032-09-04Us
US8188104 No2009-05-172029-05-17Us
US9006387 No2010-06-102030-06-10Us
US9044480 No2011-04-102031-04-10Us
US8686026 No2011-06-092031-06-09Us
US8420596 Yes2011-10-102031-10-10Us
US8691938 No2012-04-132032-04-13Us
US9629841 No2013-10-182033-10-18Us
US9333204 No2015-01-022035-01-02Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00193 mg/mLALOGPS
logP5.72ALOGPS
logP7.49ChemAxon
logS-5.7ALOGPS
pKa (Strongest Acidic)12.77ChemAxon
pKa (Strongest Basic)2.16ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area178.72 Å2ChemAxon
Rotatable Bond Count16ChemAxon
Refractivity250.79 m3·mol-1ChemAxon
Polarizability99.1 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPeptides
Alternative ParentsValine and derivatives / Proline and derivatives / Alpha amino acid amides / Phenylpyrrolidines / Anilides / Phenylpropanes / Pyrrolidinecarboxamides / Aniline and substituted anilines / N-arylamides / N-acylpyrrolidines
SubstituentsAlpha peptide / Valine or derivatives / Proline or derivatives / Alpha-amino acid amide / 2-phenylpyrrolidine / 1-phenylpyrrolidine / Anilide / Phenylpropane / Pyrrolidine carboxylic acid or derivatives / Pyrrolidine-2-carboxamide
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptorscarbamate ester, dipeptide, pyrrolidines, ring assembly, aromatic amide (CHEBI:85183 )

Targets

Kind
Protein
Organism
Hepatitis C virus
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Not Available
Gene Name:
NS5A
Uniprot ID:
Q5L478
Uniprot Name:
Nonstructural protein 5A
Molecular Weight:
48598.34 Da
References
  1. DeGoey DA, Randolph JT, Liu D, Pratt J, Hutchins C, Donner P, Krueger AC, Matulenko M, Patel S, Motter CE, Nelson L, Keddy R, Tufano M, Caspi DD, Krishnan P, Mistry N, Koev G, Reisch TJ, Mondal R, Pilot-Matias T, Gao Y, Beno DW, Maring CJ, Molla A, Dumas E, Campbell A, Williams L, Collins C, Wagner R, Kati WM: Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014 Mar 13;57(5):2047-57. doi: 10.1021/jm401398x. Epub 2014 Jan 15. [PubMed:24400777 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Uniprot Name:
Cytochrome P450 2C8
Molecular Weight:
55824.275 Da
References
  1. Shen J, Serby M, Surber B, Lee AJ, Ma J, Badri P, Menon R, Kavetskaia O, de Morais SM, Sydor J, Fischer V: Metabolism and Disposition of Pan-Genotypic Inhibitor of Hepatitis C Virus NS5A Ombitasvir in Humans. Drug Metab Dispos. 2016 Aug;44(8):1148-57. doi: 10.1124/dmd.115.067496. Epub 2016 May 13. [PubMed:27179128 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Uniprot Name:
Multidrug resistance protein 1
Molecular Weight:
141477.255 Da
References
  1. Keating GM: Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection. Drugs. 2016 Aug;76(12):1203-11. doi: 10.1007/s40265-016-0612-1. [PubMed:27401997 ]
2. UDP-glucuronosyltransferase 1A1
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
References
  1. Keating GM: Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection. Drugs. 2016 Aug;76(12):1203-11. doi: 10.1007/s40265-016-0612-1. [PubMed:27401997 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Uniprot Name:
ATP-binding cassette sub-family G member 2
Molecular Weight:
72313.47 Da
Drug created on October 30, 2015 09:54 / Updated on September 01, 2017 12:04